Cantor Fitzgerald Has Weak Outlook for PTCT FY2026 Earnings

Key Points

• Cantor Fitzgerald has revised its FY2026 earnings per share estimate for PTC Therapeutics down to ($6.71), highlighting a pessimistic outlook for the biopharmaceutical company.
• Despite the downgrade, PTC Therapeutics still holds an "Overweight" rating from Cantor Fitzgerald with a price objective of $120.00. Other analysts have varying ratings and target prices, with a consensus rating of "Moderate Buy."
• PTC's recent quarterly results exceeded expectations, with reported earnings of ($0.83) EPS, which was better than the forecasted ($1.07) EPS, indicative of resilience despite a year-over-year revenue decline.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Investment analysts at Cantor Fitzgerald cut their FY2026 earnings per share estimates for PTC Therapeutics in a research note issued on Wednesday, August 20th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn ($6.71) per share for the year, down from their prior estimate of ($6.57). Cantor Fitzgerald has a "Overweight" rating and a $120.00 price objective on the stock. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

A number of other equities analysts also recently weighed in on the stock. Truist Financial raised their target price on shares of PTC Therapeutics from $80.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Barclays raised their price objective on PTC Therapeutics from $42.00 to $46.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 29th. JPMorgan Chase & Co. lowered their price objective on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Cowen reissued a "hold" rating on shares of PTC Therapeutics in a research note on Friday, August 8th. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $63.00 price target (up from $60.00) on shares of PTC Therapeutics in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $69.15.

PTC Therapeutics Price Performance

Shares of NASDAQ PTCT opened at $48.92 on Friday. PTC Therapeutics has a 1 year low of $30.41 and a 1 year high of $58.38. The firm has a 50-day moving average of $48.87 and a 200 day moving average of $49.03. The stock has a market cap of $3.89 billion, a P/E ratio of 7.02 and a beta of 0.54.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.24. The firm had revenue of $178.88 million for the quarter, compared to analysts' expectations of $173.01 million. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The company's quarterly revenue was down 4.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.29) EPS. PTC Therapeutics has set its FY 2025 guidance at EPS.

Insider Activity

In other PTC Therapeutics news, CEO Matthew B. Klein sold 10,739 shares of the company's stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $51.74, for a total value of $555,635.86. Following the completion of the sale, the chief executive officer owned 337,767 shares in the company, valued at $17,476,064.58. This represents a 3.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Pierre Gravier sold 2,516 shares of PTC Therapeutics stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $49.46, for a total transaction of $124,441.36. Following the transaction, the chief financial officer owned 71,920 shares in the company, valued at approximately $3,557,163.20. This trade represents a 3.38% decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.

Institutional Trading of PTC Therapeutics

Several hedge funds have recently modified their holdings of the company. Wellington Management Group LLP lifted its position in PTC Therapeutics by 13.2% in the first quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company's stock worth $276,161,000 after buying an additional 632,049 shares during the last quarter. Toronto Dominion Bank bought a new stake in shares of PTC Therapeutics in the fourth quarter valued at about $148,363,000. State Street Corp lifted its position in shares of PTC Therapeutics by 22.1% in the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company's stock worth $146,347,000 after purchasing an additional 541,558 shares during the period. Janus Henderson Group PLC lifted its holdings in PTC Therapeutics by 24.4% during the fourth quarter. Janus Henderson Group PLC now owns 2,325,915 shares of the biopharmaceutical company's stock worth $105,015,000 after buying an additional 455,698 shares during the period. Finally, Geode Capital Management LLC raised its holdings in PTC Therapeutics by 3.2% in the second quarter. Geode Capital Management LLC now owns 1,934,593 shares of the biopharmaceutical company's stock worth $94,497,000 after purchasing an additional 60,707 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.